, 2005 RNA干扰(RNAi)是目前分析基因组功能及基因治疗的一个有力工具,引起基因沉默现象的小干扰RNA(siRNA)需要经过适当的化学修饰才能应用于体内。该文总结了既能稳定siRNA双链,又能有效抑制靶基因的几种常用化学修饰法,包括磷酸骨架修饰、核糖修饰和碱基修饰等。正确的修饰将会极大地促进RNAi药物从体外到体内、从实验室到临床应用的转化。siRNA作为一种很有潜力的药物将为治疗病毒性疾病、肿瘤和遗传病开辟一条崭新的道路 ...
孙莉萍, 张其清, 张秀明, 翁建
core
乙肝病毒外膜大蛋白、前S1抗原、HBV-DNA与血清标志物之间相关性分析
Zhongguo shiyan zhenduanxue, 2013 目的通过对乙型肝炎患者HBV-LP、Pre-S1抗原、HBV-DNA载量和乙型肝炎血清标志物的检测,探讨反映不同血清学类型患者体内病毒复制及抗病毒疗效监测的最佳指标以及分析各指标之间的关系。方法对864例HBV感染者及100例健康体检者血清采用ELISA法定性检测HBV-M;ELISA双抗体夹心法检测HBV-LP、Pre-S1;荧光定量PCR法检测HBV-DNA。结果 HBsAg、HBeAg、HBcAb阳性模式组(大三阳)HBV-LP、Pre-S1及HBVDNA阳性率显著高于其它HBV-M模式组(P0 ...
龚杰, 刘柏林, 方艳秋, 杨广民
doaj
Zhongguo shiyan zhenduanxue, 2007 目的研究HBV前S1抗原检测的临床价值,即HBVPreS1抗原与具有病毒活动性复制意义的指标HBeAg和HBV-DNA之间的相关性其与肝功能指标ALT之间的关系。方法HBV前S1抗原和血清标志物（HBsAg、HBsAb、HBeAg、HBeAb、HBcAb-IgG、HBcAb-IgM）采用ELISA法检测;肝功能（ALT）用酶学速率法检测;HBV DNA用荧光定量PCR法检测。结果①HBeAg阳性组其HBV PreS1抗原检出率高。②HBV PreS1抗原与具有病毒活动性复制意义的指标HBV ...
崔红花, 王晶莹, 谢风
doaj
[Expert consensus on the management process within medical institutions for patients with hepatitis B virus infection]. [PDF]
Zhonghua Gan Zang Bing Za ZhiAuthor Group of Expert Consensus.
europepmc +1 more source
[Progress in clinical research related to viral hepatitis in 2025]. [PDF]
Zhonghua Gan Zang Bing Za ZhiDing Y, Li Y, Dou XG.
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 1995 对１２８例有病理诊断依据的肝细胞场（ＨＣＣ）、４７例慢迁肝（ＣＰＨ）、１０５例慢活肝（ＣＡＨ）、４６例肝硬化（ＬＣ）．采用嵌套式ＰＣＲ技术检测其血标本中的丙型肝炎病毒（ＨＣｖ）ＲＮＡ和乙型肝炎病毒（ＨＢＶ）ＤＩＩＡ，对这两种病毒的血清学标志也进行了研究。结果：在ＨＣＣ组。ＨＣＶＲＮＡ１４．１％阳性，ＨＢＶＤＮＡ７ｉ．３％阳性。ＣＰＨ，ＣＡＨ，ＬＣ和ＨＣＣ的ＨＢＶ感染率均在９０％左右，而ＨＣＶ感染率则分别为８．５％、９．５％、１７．４％和１９．５％，显示ＨＣＶ感染率随肝病严重程度的增加而有增加的趋势 ...
doaj
[Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B]. [PDF]
Zhonghua Gan Zang Bing Za ZhiWang ZW +11 more
europepmc +1 more source
[Analysis of antiviral efficacy in pediatric patients with HBeAg-negative chronic hepatitis B]. [PDF]
Zhonghua Gan Zang Bing Za ZhiGuo X +8 more
europepmc +1 more source
[Advances in clinical features, diagnosis, and treatment of pre-acute-on-chronic liver failure]. [PDF]
Zhonghua Gan Zang Bing Za ZhiNie YH, Cai DC.
europepmc +1 more source
[Reflections on the novel definition and whether or not antiviral therapy for inactive HBsAg carrier state in the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)"]. [PDF]
Zhonghua Gan Zang Bing Za ZhiRen S, Zheng SJ, Chen XY.
europepmc +1 more source